Get the Stockscreener App
5.62
0.18%
0.010
Pulmatrix Inc stock is traded at $5.62, with a volume of 6,560.
It is up +0.18% in the last 24 hours and down -17.84% over the past month.
Pulmatrix Inc is a biopharmaceutical company that has focused on the development of novel inhaled therapeutic products intended to prevent and treat migraine and respiratory diseases with important unmet medical needs using its patented dry powder delivery technology, iSPERSE. Its pipeline of clinical assets includes PUR3100 for the treatment of acute migraine, PUR1800 for the treatment of acute exacerbations of chronic obstructive pulmonary disease (AECOPD), and PUR1900 for the treatment of ABPA in patients with asthma and in patients with cystic fibrosis (CF).
See More
Previous Close:
$5.61
Open:
$5.61
24h Volume:
6,560
Relative Volume:
0.23
Market Cap:
$20.53M
Revenue:
$11.68M
Net Income/Loss:
$-8.85M
P/E Ratio:
-2.332
EPS:
-2.41
Net Cash Flow:
$-14.61M
1W Performance:
-9.50%
1M Performance:
-17.84%
6M Performance:
-22.80%
1Y Performance:
+166.35%
1-Day Range:
$5.61
$5.80
1-Week Range:
$5.60
$6.30
52-Week Range:
$1.78
$10.40
Pulmatrix Inc Stock (PULM) Company Profile
Name
Pulmatrix Inc
Sector
Industry
Phone
(888) 355-4440
Address
945 CONCORD STREET, FRAMINGHAM, MA
Compare PULM with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PULM
Pulmatrix Inc
|
5.62 | 20.49M | 11.68M | -8.85M | -14.61M | -2.41 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.65 | 121.28B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.10 | 60.96B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
328.81 | 42.77B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
591.99 | 36.21B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
291.47 | 32.08B | 3.81B | -644.79M | -669.77M | -6.24 |
Pulmatrix Inc Stock (PULM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-09-18 | Initiated | H.C. Wainwright | Buy |
Pulmatrix Inc Stock (PULM) Latest News
Pulmatrix Inc. Stock Analysis and ForecastTremendous growth potential - PrintWeekIndia
Is Pulmatrix Inc. a good long term investmentOverwhelming financial success - Autocar Professional
What makes Pulmatrix Inc. stock price move sharplyFree Real-Time Trading Opportunities - Newser
What drives Pulmatrix Inc. stock priceTremendous growth potential - Autocar Professional
What analysts say about Pulmatrix Inc. stockExtraordinary profit generation - Autocar Professional
What analysts say about Pulmatrix Inc. stock outlookCapital Preservation Investment Ideas - Newser
Long Term Trading Analysis for (PULM) - news.stocktradersdaily.com
Reviewing Pulmatrix (NASDAQ:PULM) and Vanda Pharmaceuticals (NASDAQ:VNDA) - Defense World
How high can Pulmatrix Inc. stock price go in 2025High Yield Opportunities - Newser
Why Pulmatrix Inc. stock attracts strong analyst attentionFree Investment Portfolio Suggestions - beatles.ru
How Pulmatrix Inc. stock performs during market volatilityFree Access to Community with 300% Return - Newser
(PULM) Technical Data - news.stocktradersdaily.com
PULM Trading Resumes: Pulmatrix Updates Investors | PULM Stock News - GuruFocus
Pulmatrix (PULM) Trading Halted Due to Volatility | PULM Stock News - GuruFocus
Pulmatrix (PULM) Trading Resumes as Investors Watch Closely | PULM Stock News - GuruFocus
PULM Trading Temporarily Halted Due to Volatility | PULM Stock News - GuruFocus
PULM Trading Temporarily Halted Due to Volatility | PULM Stock N - GuruFocus
How to Take Advantage of moves in (PULM) - news.stocktradersdaily.com
Learn to Evaluate (PULM) using the Charts - news.stocktradersdaily.com
Financial Comparison: Pulmatrix (NASDAQ:PULM) & Acelyrin (NASDAQ:SLRN) - Defense World
Pulmatrix (NASDAQ:PULM) Now Covered by StockNews.com - Defense World
(PULM) Trading Advice - news.stocktradersdaily.com
Pulmatrix set for merger with Cullgen, seeks asset divestment By Investing.com - Investing.com South Africa
Enliven stops work on solid tumor drug; Pulmatrix to divest assets - Endpoints News
Pulmatrix Announces Divestment Plan for Assets - citybiz
Pulmatrix Announces First Quarter 2025 Financial Results and Div - GuruFocus
Pulmatrix Inc Stock (PULM) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.97%
0.22%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):